High-speed reliable detection of cancer cells in blood

高速可靠地检测血液中的癌细胞

基本信息

批准号：
7642499
负责人：
Richard H. Bruce
金额：
$ 77.72万
依托单位：
PALO ALTO RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-09-06 至 2011-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7642499
关键词：
Antigens Area Automation Biomedical Engineering Blood Blood Cells Blood specimen Cancer Center Cancer Patient Cancer Research Project Cell Count Cell Line Cells Clinic Clinical Clinical Oncology Collaborations Computer software Data Detection Development Diagnostic Neoplasm Staging Disclosure Disease Disseminated Malignant Neoplasm Doctor of Philosophy Engineering Enrollment Fiber Heterogeneity Human Image Incidence Institution Label Lead Malignant Neoplasms Measures Mechanics Medical Medicine Methods Microscopy Monitor Optics Pathology Patients Performance Population Preparation Prevalence Principal Investigator Procedures Process Protocols documentation Publishing Recurrent disease Relapse Reporting Research Research Institute Research Personnel Research Subjects Resolution Risk Sampling Scanning Screening for cancer Specificity Specimen Handling Speed Stage at Diagnosis Staging System Technology Time Validation Visual base burden of illness cancer cell cell preparation cohort computerized data processing cost design experimental analysis high risk improved instrument interdisciplinary approach malignant breast neoplasm method development multidisciplinary neoplastic cell new technology oncology peripheral blood programs prototype response

项目摘要

DESCRIPTION (provided by applicant): The medical value of detecting circulating tumor cells (CTCs) in peripheral blood is now established, and a specific approach has FDA approval for managing metastatic patients. While the value is clear, it is also limited in application. For example, the reported results are uninformative for a large percentage of metastatic patients, and no validation exists for earlier stages. The cancer bioengineering research partnership (CBRP) proposes to develop a technology for CTC detection that overcomes these limitations. We will develop a new instrument, the Fiber Array Scan Technology (FAST) cytometer that efficiently scans the large numbers of cells required to detect CTCs and a cell preparation protocol that is optimized for cell retention. We will use these developments to investigate whether more metastatic patients have CTCs than current approaches indicate. We will also investigate the medical efficacy of CTC detection in early stage cancer patients. In addition we will investigate applications for staging at diagnosis, as well as for longitudinal therapy monitoring and long-term patient management. The effort integrates clinical oncology with biophysical analysis methods and opto-mechanical engineering. The CBRP will develop a rare cell detection system that can analyze approximately 50 million cells in 2 minutes with a sensitivity of 10% false negatives and a false positive ratio of less than 1 in 107. The Lead Investigators of the CBRP have developed the initial proof of concept through a multidisciplinary approach bridging optical design, statistical software analysis, experimental medicine, oncology, and pathology at the leading institutions, the Palo Alto Research Center (PARC) and The Scripps Research Institute (TSRI), as well as at the participating institutions, Scripps Clinic and the Scripps Cancer Center. The lead investigators are Richard Bruce, Ph.D. (PARC), who is the principal investigator and will in addition lead the optical and system engineering efforts; Peter Kuhn, Ph.D. (TSRI), who will lead the experimental processing; and Jorge Nieva, MD (TSRI and Scripps Cancer Center), who will lead the oncology and pathology of the CBRP. The lead investigators are experts in their respective fields and provide the required expertise for the multi-disciplinary research program of the CBRP.

描述（由申请人提供）：检测外周血中循环肿瘤细胞（CTC）的医学价值现已确立，并且 FDA 批准了一种用于管理转移患者的具体方法。虽然其价值显而易见，但其应用也受到限制。例如，报告的结果对于大部分转移性患者来说并没有提供任何信息，并且对于早期阶段也没有验证。癌症生物工程研究伙伴关系 (CBRP) 提议开发一种克服这些限制的 CTC 检测技术。我们将开发一种新仪器，即光纤阵列扫描技术 (FAST) 细胞仪，可有效扫描检测 CTC 所需的大量细胞，并开发针对细胞保留进行优化的细胞制备方案。我们将利用这些进展来调查是否有比目前方法显示的更多的转移性患者具有 CTC。我们还将研究CTC检测对早期癌症患者的医疗效果。此外，我们将研究诊断分期以及纵向治疗监测和长期患者管理的应用。这项工作将临床肿瘤学与生物物理分析方法和光机械工程相结合。 CBRP 将开发一种稀有细胞检测系统，可在 2 分钟内分析约 5000 万个细胞，假阴性灵敏度为 10%，假阳性率低于 107 分之一。 CBRP 的首席研究员已开发出初步证据通过帕洛阿尔托研究中心 (PARC) 和斯克里普斯研究所等领先机构的多学科方法，将光学设计、统计软件分析、实验医学、肿瘤学和病理学联系起来（TSRI）以及参与机构斯克里普斯诊所和斯克里普斯癌症中心。首席研究员是理查德·布鲁斯博士。（帕洛阿尔托研究中心），他是首席研究员，此外还将领导光学和系统工程工作；彼得·库恩博士（TSRI），谁将领导实验处理； Jorge Nieva 医学博士（TSRI 和斯克里普斯癌症中心）将领导 CBRP 的肿瘤学和病理学工作。首席研究员是各自领域的专家，为 CBRP 的多学科研究项目提供所需的专业知识。